Phase II data with ZD6474, a small-molecule kinase inhibitor of epidermal growth factor receptor and vascular endothelial growth factor receptor, in previously treated advanced non-small-cell lung cancer

Clinical Lung Cancer

Volumn 7, Issue 2, 2005, Pages 89-91

  Lee, David ^a   Natale, Ronald B ^a   Nadler, Eric ^a   Jain, Vinay K ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

CARBOPLATIN; DOCETAXEL; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; GEFITINIB; PACLITAXEL; PLACEBO; PLATINUM; VANDETANIB; VASCULOTROPIN INHIBITOR;

ADULT; AGED; ARTICLE; CANCER SURVIVAL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DOUBLE BLIND PROCEDURE; DRUG ERUPTION; DRUG MECHANISM; DRUG MEGADOSE; DRUG RESPONSE; DRUG STRUCTURE; DRUG TARGETING; FEMALE; HUMAN; HYPERTENSION; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; MULTICENTER STUDY; NAUSEA AND VOMITING; OUTCOME ASSESSMENT; PATIENT SELECTION; PHASE 2 CLINICAL TRIAL; QT PROLONGATION; RANDOMIZED CONTROLLED TRIAL;

EID: 32044467693     PISSN: 15257304     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1525-7304(11)70394-1     Document Type: Article

References (5)

1. Wedge SR, Ogilvie DJ, Dukes M, et al. ZD6474 inhibits vascular endothelial growth factor signaling, angiogenesis, and tumor growth following oral administration. Cancer Res 2002; 62:4645-55.
2. Holden SN, Eckhardt SG, Basser R, et al. Clinical evaluation of ZD6474, an orally active inhibitor of VEGF and EGF receptor signaling, in patients with solid, malignant tumors. Ann Oncol 2005; 16:1391-1397.
3. Minami H, Ebi H, Tahara M, et al. A phase I study of an oral VEGF receptor tyrosine kinase inhibitor ZD6474, in Japanese patients with solid tumors. Proc Am Soc Clin Oncol 2003; 22:194 (Abstract #778).
4. Natale R, Bodkin D, Govindan R, et al. A comparison of the antitumour efficacy of ZD6474 and gefitinib (Iressa™) in patients with NSCLC: results of a randomized, double-blind phase II study. Lung Cancer 2005; 49(suppl 2):537 (Abstract #O-103).
5. Herbst R, Johnson B, Rowbottom J, et al. ZD6474 plus docetaxel in patients with previously treated NSCLC: results of a randomized, placebo-controlled phase II trial. Lung Cancer 2005; 49(suppl 2):535 (Abstract #O-100).